Bumetanide Injection · #10 of 35 active shortages by FDA posting duration
Brand: BUMETANIDE
FDA lists Bumetanide Injection as Active Shortage (Hikma Pharmaceuticals USA, Inc.).
Availability on file: Available
Bumetanide Injection: Active Shortage
Available 17 shortage presentations are tracked for this drug. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Bumetanide Injection
- Manufacturer
- Hikma Pharmaceuticals USA, Inc.
- Dosage Form
- Injection
- Presentation
- Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)
- Package NDC
- 0641-6007-10
Status & Timeline
- Status
- Active Shortage
- Availability
- Available
- First Reported
- Jan 31, 2018
- Last Updated
- Mar 12, 2026
- Therapeutic Category
- Cardiovascular
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.
Full Drug Profile
bumetanide
Side effects, interactions, warnings & more
Nearby, Other Bumetanide Shortage Records
Bumetanide Injection
Fresenius Kabi USA, LLC
Injection
Bumetanide Injection
Fresenius Kabi USA, LLC
Injection
Bumetanide Injection
Mullan Pharmaceutical Inc.
Injection
Bumetanide Injection
Mullan Pharmaceutical Inc.
Injection
Bumetanide Injection
Hikma Pharmaceuticals USA, Inc.
Injection
Bumetanide Injection
Sagent Pharmaceuticals
Injection
FDA reason on file: Additional lots are scheduled for manufacturing to meet demand. General shortage guidance lives on the tracker hub.